Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. Spencer Grant | Universal Images Group | Getty Images Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U.S. Food and Drug Administration. …